Skip to main content

Atara Biotherapeutics, Inc.

ATRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001604464

In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Atara Biotherapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of ATRA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders151145−6
Shares86.7M86.0M−654.8K (−0.8%)
Value$1.24B$1.34B+$93.0M (+7.5%)

New holders (18)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to ATRA in Q2 2021
InstitutionSharesValue% of portfolio
Assenagon Asset Management S.A.1,496,924$23.3M0.10%
ACT Capital Management, LLC116,900$1.82M0.93%
Alps Advisors Inc110,734$1.72M0.02%
Jupiter Asset Management Ltd101,213$1.57M0.02%
Alpha Paradigm Partners, LLC97,980$1.52M0.57%
Copernicus Capital Management, LLC50,000$778.0K12.27%
QS Investors, LLC30,500$475.0K0.01%
Blueshift Asset Management, LLC22,451$349.0K0.02%
HRT Financial LP17,335$269.0K0.00%
Virginia Retirement Systems Et Al16,000$249.0K0.00%
Private Capital Advisors, Inc.15,000$233.0K0.04%
Virtu Financial LLC12,680$197.0K0.02%
ExodusPoint Capital Management, LP12,438$193.0K0.00%
Algert Global LLC12,170$189.0K0.06%
Amundi11,913$185.0K0.00%
Dark Forest Capital Management LP7,523$117.0K0.05%
NEXT Financial Group, Inc6,707$105.0K0.01%
Meeder Asset Management Inc309$5.00K0.00%

Sold out (24)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.